GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

Core Insights - Grail, Inc. experienced a significant decline in stock value, losing approximately 50% of its market capitalization after the announcement that the NHS Galleri trial did not meet its primary endpoint [1] Financial Performance - The company projected a cash burn of no more than $290 million, indicating potential financial strain while guiding to milestones that may have been at risk [1]